fda 503a bulks list bpc-157 category 2 FDA's own advisory committee voted 8-6 Thursday. BPC-157, on the compounding now, for ulcerative colitis. staff argued against it, laid out the data gaps, the whole case. Panel overruled them 3 FOR 3. An FDA

3 FOR 3. An FDA advisory committee has now voted 86, with one abstention, to recommend BPC 157, KPV and TB 500 for inclusion on the 503A Bulks List. This is not FDA approval BPC 157 PASSED! Gabriel Alizaidy, MD, MS I also agree with you, the FDA's data pitch was very disappointing For the compounding industry, this is a positive vote. It does not immediately make The Food and Drug Administration's committee on compounded drugs broke with agency scientists and voted in favor of adding peptides to the list of substances compounding pharmacies can make. Follow the link FDA Removes 12 Peptides from 503A List, PCAC Review to Follow Kurt Lunkwitz posted on the topic LinkedIn

SKU: 15835754148 · From composequickly.com